MOTS-c

The original 2015 MOTS-c study investigated the peptide in relation to metabolic homeostasis. Researchers found that MOTS-c affected pathways involving AMP-activated protein kinase (AMPK), an important cellular energy sensor.

In mouse experiments, MOTS-c administration was associated with improved insulin sensitivity and protection against high-fat-diet-induced obesity and age-associated insulin resistance. This study helped generate much of the subsequent scientific interest in MOTS-c.

Skeletal muscle appears to be an important target in MOTS-c research. Experimental work suggests MOTS-c may affect glucose utilization and metabolic pathways in muscle through mechanisms involving AMPK and the folate-purine pathway.

This has led researchers to investigate whether mitochondrial-derived peptides could eventually help explain relationships between exercise, metabolism, insulin sensitivity, muscle function and aging. That remains an active research question rather than an established therapeutic application.

Exercise is one of the more interesting areas of human MOTS-c research. Human studies have measured the body's naturally occurring MOTS-c before and after metabolic challenges or exercise.

A study involving women with polycystic ovary syndrome and healthy controls examined how circulating MOTS-c responded to lipids, insulin, and an eight-week exercise program. The researchers observed metabolic changes in circulating MOTS-c, although exercise training itself did not produce a consistent long-term increase in levels.

A 2026 systematic review of mitochondrial-derived peptides and physical exercise found that many studies reported increases in mitochondrial-derived peptide levels following exercise, but emphasized that the number and quality of human studies remain limited and results vary according to study design and population.

Studies measuring naturally produced MOTS-c in people are not evidence that injecting or administering synthetic MOTS-c produces the same effects. Those are two different scientific questions.

MOTS-c has been investigated extensively in laboratory and animal models of insulin resistance and metabolic dysfunction. The original research showed effects involving glucose metabolism, skeletal-muscle glucose utilization, AMPK activation, insulin sensitivity, and fat metabolism.

Human observational studies have also found relationships between circulating MOTS-c concentrations and metabolic conditions. However, the results are not always consistent. A 2024 systematic review and meta-analysis involving 602 participants found that circulating MOTS-c differed among people with diabetes and obesity, but the direction of the relationship varied by metabolic condition. The authors concluded that more research is needed.

MOTS-c is frequently discussed online as a “weight-loss peptide.” That description goes beyond the current human evidence. Mouse experiments have shown effects on diet-induced obesity and metabolic dysfunction.

However, FDA's 2026 review specifically searched for clinical evidence involving MOTS-c administration for obesity and found no human clinical studies evaluating administered MOTS-c for that purpose.

MOTS-c has also been investigated in preclinical models involving bone formation and osteoporosis. FDA's scientific review noted animal research suggesting effects involving osteogenesis and osteolysis, which helped prompt interest in MOTS-c for bone biology.

Current evidence should therefore be described as preclinical and investigational.

Mitochondrial dysfunction is strongly associated with aging biology, which has made mitochondrial-derived peptides a major area of longevity research. Reviews have examined MOTS-c in connection with cellular stress resilience, metabolic homeostasis, muscle function, mitochondrial signaling, and age-associated metabolic changes.

Researchers are also studying whether naturally circulating MOTS-c might serve as a biomarker related to cardiovascular or metabolic health. A 2024 multicenter observational study involving 94 patients receiving hemodialysis found an association between circulating MOTS-c levels and cardiovascular/mortality outcomes.

Importantly, the researchers were measuring endogenous MOTS-c, not administering MOTS-c as treatment.